Aerska website screenshot

Aerska

Aerska is a biotechnology company developing RNA interference (RNAi) medicines to treat, delay, and prevent diseases of the brain and central nervous system. The company pairs next-generation RNAi therapeutics with receptor-mediated "brain shuttle" delivery technology engineered to cross the blood-brain barrier and silence disease-causing genes in the CNS. Founded in 2025 by Jack O'Meara, Stuart Milstein, and Dave Hardwicke, Aerska is headquartered in Dublin, Ireland with research operations in London. It emerged from stealth in 2026 having raised a Series A round led by the EQT Dementia Fund and age1, with additional backing from Speedinvest and Backed. Aerska is a pre-clinical drug-discovery company and does not currently publish a public developer API or platform.

Aerska is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, RNA Interference, and Therapeutics.

Aerska’s developer surface includes engineering blog and 5 more developer resources.

🌐 Visit website 📡 Source on GitHub
14.3/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyBiotechnologyPharmaceuticalsRNA InterferenceTherapeuticsCentral Nervous SystemDrug DiscoveryLife Sciences

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 14.3/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.4 / 20
Commercial Clarity 4.2 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/aerska: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Aerska Domain Security

TLSv1.3 · HSTS · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Commercial 2

Pricing, plans, and the legal terms of use

TermsOfService
TermsOfService
 PrivacyPolicy
PrivacyPolicy

Company 3

The organization behind the API

Website
Website
 Blog
Blog
 LinkedIn
LinkedIn

Source (apis.yml)

apis.yml Raw ↑ 
aid: aerska
name: Aerska
description: Aerska is a biotechnology company developing RNA interference (RNAi) medicines to treat, delay, and prevent diseases
  of the brain and central nervous system. The company pairs next-generation RNAi therapeutics with receptor-mediated "brain
  shuttle" delivery technology engineered to cross the blood-brain barrier and silence disease-causing genes in the CNS. Founded
  in 2025 by Jack O'Meara, Stuart Milstein, and Dave Hardwicke, Aerska is headquartered in Dublin, Ireland with research operations
  in London. It emerged from stealth in 2026 having raised a Series A round led by the EQT Dementia Fund and age1, with additional
  backing from Speedinvest and Backed. Aerska is a pre-clinical drug-discovery company and does not currently publish a public
  developer API or platform.
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://cdn.prod.website-files.com/689223822062a164aff49efd/68a87c64ca12cfd483266888_Aerska%20Design.png
url: https://raw.githubusercontent.com/api-evangelist/aerska/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- speedinvest
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-17'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- RNA Interference
- Therapeutics
- Central Nervous System
- Drug Discovery
- Life Sciences
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://aerska.com
- type: Blog
  url: https://www.aerska.com/news
- type: TermsOfService
  url: https://www.aerska.com/legal/terms-and-conditions
- type: PrivacyPolicy
  url: https://www.aerska.com/legal/privacy-policy
- type: LinkedIn
  url: https://www.linkedin.com/company/aerska/
- type: DomainSecurity
  url: security/aerska-domain-security.yml
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence